A Meta-Analysis of Adalimumab for Fistula in Crohn’s Disease
Purpose. This study aimed to evaluate the therapeutic value of adalimumab (ADA) for fistula in Crohn’s disease (CD). Methods. A computerized search of electronic databases, including PubMed, Web of Science, Embase, Google scholar, and the Cochrane Library from 2000 to October 2016, was performed. Ra...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2017/1745692 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565037477134336 |
|---|---|
| author | Yin-mei Fu Ming Chen Ai-jun Liao |
| author_facet | Yin-mei Fu Ming Chen Ai-jun Liao |
| author_sort | Yin-mei Fu |
| collection | DOAJ |
| description | Purpose. This study aimed to evaluate the therapeutic value of adalimumab (ADA) for fistula in Crohn’s disease (CD). Methods. A computerized search of electronic databases, including PubMed, Web of Science, Embase, Google scholar, and the Cochrane Library from 2000 to October 2016, was performed. Randomized controlled trials (rcts) or nonrandomized controlled trials (n-rcts) were included in this article to evaluate the role of ADA in the management of fistula in CD. The methodological index for nonrandomized studies (MINORS evaluation tools) was used to assess the quality of every study. Result. Overall, seven studies and 379 patients comforted to the inclusion criteria of this meta-analysis. The result showed that 36% (95% CI: 0.31–0.41) of patients with complete fistula closure and 31% (95% CI: 0.031–0.61) of patients with partial response were received in CD with ADA treatment. Conclusion. We concluded that ADA is effective and safe for the treatment of fistula in CD according to current evidence. |
| format | Article |
| id | doaj-art-7e0aaa9e92c542ada169c55b46e91252 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-7e0aaa9e92c542ada169c55b46e912522025-02-03T01:09:37ZengWileyGastroenterology Research and Practice1687-61211687-630X2017-01-01201710.1155/2017/17456921745692A Meta-Analysis of Adalimumab for Fistula in Crohn’s DiseaseYin-mei Fu0Ming Chen1Ai-jun Liao2Department of Gastroenterology and Hepatology, First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, ChinaDepartment of Gastroenterology and Hepatology, First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, ChinaDepartment of Gastroenterology and Hepatology, First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, ChinaPurpose. This study aimed to evaluate the therapeutic value of adalimumab (ADA) for fistula in Crohn’s disease (CD). Methods. A computerized search of electronic databases, including PubMed, Web of Science, Embase, Google scholar, and the Cochrane Library from 2000 to October 2016, was performed. Randomized controlled trials (rcts) or nonrandomized controlled trials (n-rcts) were included in this article to evaluate the role of ADA in the management of fistula in CD. The methodological index for nonrandomized studies (MINORS evaluation tools) was used to assess the quality of every study. Result. Overall, seven studies and 379 patients comforted to the inclusion criteria of this meta-analysis. The result showed that 36% (95% CI: 0.31–0.41) of patients with complete fistula closure and 31% (95% CI: 0.031–0.61) of patients with partial response were received in CD with ADA treatment. Conclusion. We concluded that ADA is effective and safe for the treatment of fistula in CD according to current evidence.http://dx.doi.org/10.1155/2017/1745692 |
| spellingShingle | Yin-mei Fu Ming Chen Ai-jun Liao A Meta-Analysis of Adalimumab for Fistula in Crohn’s Disease Gastroenterology Research and Practice |
| title | A Meta-Analysis of Adalimumab for Fistula in Crohn’s Disease |
| title_full | A Meta-Analysis of Adalimumab for Fistula in Crohn’s Disease |
| title_fullStr | A Meta-Analysis of Adalimumab for Fistula in Crohn’s Disease |
| title_full_unstemmed | A Meta-Analysis of Adalimumab for Fistula in Crohn’s Disease |
| title_short | A Meta-Analysis of Adalimumab for Fistula in Crohn’s Disease |
| title_sort | meta analysis of adalimumab for fistula in crohn s disease |
| url | http://dx.doi.org/10.1155/2017/1745692 |
| work_keys_str_mv | AT yinmeifu ametaanalysisofadalimumabforfistulaincrohnsdisease AT mingchen ametaanalysisofadalimumabforfistulaincrohnsdisease AT aijunliao ametaanalysisofadalimumabforfistulaincrohnsdisease AT yinmeifu metaanalysisofadalimumabforfistulaincrohnsdisease AT mingchen metaanalysisofadalimumabforfistulaincrohnsdisease AT aijunliao metaanalysisofadalimumabforfistulaincrohnsdisease |